ABPath Clinical Pathology common mistakes
ABPath Clinical Pathology · Understand the traps and how to avoid them.
When given a case with an abnormal coagulation profile, selecting the diagnosis from the pattern alone without first deciding whether the prolongation corrects on a 1:1 mixing study, so that a factor deficiency and a circulating inhibitor are conflated.
The mixing study is the branch point of the coagulation algorithm, but candidates under time pressure jump from prolonged PTT to 'hemophilia' or 'lupus anticoagulant' based on partial clinical cues, skipping the single test that separates the two pathways.
What to do instead
Before answering, write the two-step logic explicitly: does the abnormal screen correct at 1:1 (deficiency) or not (inhibitor)? Then apply the confirmatory branch (factor assays for deficiency; inhibitor screen, Bethesda titer, or phospholipid-dependence testing for inhibitor). Rehearse this as a fixed script on every coag question.
Reading an arterial blood gas by the pH alone and labeling the primary disorder without systematically checking the compensation (expected pCO2 for the metabolic disorder, expected HCO3 for the respiratory disorder) and the anion gap.
Compensation formulas are memorized as isolated facts and are not retrieved under time pressure, and mixed disorders are missed because candidates stop at the first abnormality rather than testing whether the secondary response is appropriate.
What to do instead
Use a fixed four-step worksheet on every acid-base item: pH direction, primary process, expected compensation (calculate it), then anion gap and delta gap. If the measured compensation falls outside the predicted range, commit to a mixed disorder rather than forcing a single label.
Classifying an anemia by morphologic pattern (microcytic, normocytic, macrocytic) without integrating the reticulocyte response and the iron-study sequence, leading to mislabeling anemia of chronic disease as iron deficiency or vice versa.
Candidates memorize individual iron-study values rather than the relationships among ferritin, TIBC, transferrin saturation, and retic count, and they anchor on the MCV before establishing whether the marrow is responding.
What to do instead
Always compute or state the corrected reticulocyte index first, then place the case in the hypoproliferative versus regenerative branch, then apply iron studies. For ambiguous iron profiles, reason explicitly about ferritin as an acute-phase reactant and use the Mentzer index or soluble transferrin receptor only as supporting, not primary, evidence.
Interpreting a peripheral smear or flow cytometry panel by pattern-matching a single finding (e.g., Auer rod, smudge cell, CD5 coexpression) to a diagnosis without confirming that the full immunophenotype or morphologic context is concordant.
Board items deliberately include findings that are characteristic but not pathognomonic; candidates who stop at the first recognizable feature miss the distractor that makes the case a variant or a different entity.
What to do instead
For each smear or flow item, list the diagnostic criteria the entity requires and check them off against the stem. If a criterion is absent or contradicted, downgrade the favored diagnosis and reconsider. Practice building the full criteria list before selecting an answer.
Choosing an empiric antimicrobial or interpreting a susceptibility result without first settling the organism identification and the specimen-source context (contaminant versus pathogen, community versus nosocomial, intrinsic resistance).
Candidates treat susceptibility tables as the answer key and forget that intrinsic resistance and source context determine which drugs are even reportable, so they select a drug that the organism is intrinsically resistant to or that is inappropriate for the site.
What to do instead
Before answering, state the organism, its intrinsic resistance profile, and the specimen source. Then eliminate any drug that is intrinsically inactive or not reported for that source. Treat the susceptibility panel as a confirmation step, not the starting point.
On a serology or antigen-detection question, interpreting a single positive or negative result without accounting for the window period, prior vaccination or passive antibody, and the pretest probability implied by the clinical scenario.
Candidates reason from test result to diagnosis in one step and ignore that sensitivity and specificity change the meaning of a result depending on prevalence and timing, so they misclassify a false positive as disease or dismiss a true early infection.
What to do instead
For every serology item, explicitly state the stage of infection (acute, convalescent, remote), whether the assay detects IgM, IgG, or antigen, and the pretest probability. Use paired sera or nucleic acid testing to resolve discordance rather than committing on one result.
Resolving an antibody identification panel by picking the antibody that fits most reactions without performing the exclusion process (rule out by phase and zygosity, check for dosage, and assess whether a second antibody or an alloantibody plus autoantibody is present).
Candidates pattern-match the column with the most positive cells and stop, missing that a single antibody must explain all reactive cells and no nonreactive cells, and overlooking dosage effects on homozygous versus heterozygous cells.
What to do instead
Work the panel systematically: exclude specificities using nonreactive cells first, then confirm with homozygous (dosage) cells, then test whether the remaining reactions require a second antibody. Only accept a single specificity when it explains every reaction and every nonreaction at the appropriate phase.
On a transfusion-reaction or hemolytic-disease-of-the-newborn question, selecting the diagnosis from the clinical picture without matching it to the serologic and laboratory pattern (DAT result, eluate, antibody class, and timing of the reaction).
Candidates conflate delayed hemolytic, acute hemolytic, febrile nonhemolytic, and TRALI patterns because they reason from symptoms rather than from the defining laboratory findings and timing that separate them.
What to do instead
Build a timing-and-findings grid before answering: immediate versus delayed, DAT positive versus negative, intravascular versus extravascular hemolysis, and antibody class. Match the stem to the grid and eliminate categories that the timing or DAT result excludes.
Interpreting a molecular or cytogenetic result without connecting the assay's limitations to the clinical question, e.g., treating a negative targeted panel as excluding a diagnosis, or misreading a variant of uncertain significance as pathogenic.
Candidates treat molecular results as binary and forget that test sensitivity depends on the assay's scope (targeted versus sequencing, deletion versus point mutation), and they do not apply ACMG-style classification logic to variants.
What to do instead
For each molecular item, state what the assay can and cannot detect, whether the result is germline or somatic, and how the variant is classified. A negative targeted test excludes only what the assay covers; a VUS is not a diagnosis. Practice stating the scope limitation before selecting an answer.
Answering laboratory-management and informatics items by choosing the option that sounds operationally ideal rather than applying the specific regulatory or statistical framework the item tests (e.g., QC rule selection, proficiency testing failure thresholds, or validation requirements).
These topics feel like common sense, so candidates skip the formal framework and pick plausible-sounding answers; they also misapply Westgard rules or confuse regulatory categories because the rules were memorized as names rather than decision logic.
What to do instead
For QC items, identify which error type (random versus systematic) the rule detects and whether the rule is sensitive to the shift shown. For regulatory items, anchor to the specific requirement (validation before reporting, PT failure triggers, corrective action) rather than general best practice. Build a one-page decision table for QC rules and regulatory categories and drill it.